Search Results for "ATTRv"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Evaluation of Disease Progression in Patients with ATTR Amyloidosis with Cardiomyopathy Following Treatment with Patisiran: Post hoc Analysis of the APOLLO-B Study

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

Transition between Patisiran and Vutrisiran

Standard response letter on transitioning between patisiran and vutrisiran therapy.

Patisiran: APOLLO-B Study

Standard response letter on patisiran and the APOLLO-B study, a study evaluating the efficacy and safety of patisiran in patients with ATTR with cardiomyopathy, including both hATTR and wtATTR.

Patisiran Global Open-Label Extension Study at 36 Months: Effect of Long-Term Treatment on Mortality and Ambulatory Function in Patients with hATTR Amyloidosis with Polyneuropathy

Vutrisiran: Use in Patients with Renal Impairment

Standard response letter on vutrisiran and use in patients with renal impairment.

HELIOS-A: 9-Month Results from the Randomized Treatment Extension Period of Vutrisiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

Patisiran: APOLLO Study Results

Standard response letter on patisiran and the APOLLO study, a phase 3 study evaluating the efficacy and safety of patisiran in patients with the polyneuropathy of hATTR.

Patisiran: APOLLO-B OLE Study

Standard response letter on the APOLLO-B OLE study of patisiran.

Musculoskeletal manifestations in patients with ATTR amyloidosis: Evidence from real-world analyses and clinical trials

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.